ALKS

34.03

1.22% 0.41

Dopo l'orario di chiusura: 34.11 0.08 +0.24%

Alkermes Plc (ALKS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ALKS Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$33.62

Aprire:

$33.52

Volume 24 ore:

1.63M

Relative Volume:

1.04

Capitalizzazione di mercato:

$5.53B

Reddito:

$1.51B

Utile/perdita netta:

$333.35M

Rapporto P/E:

17.45

EPS:

1.95

Flusso di cassa netto:

$315.22M

1 W Prestazione:

-0.93%

1M Prestazione:

-5.18%

6M Prestazione:

+23.03%

1 anno Prestazione:

+17.83%

Intervallo 1D:

$33.26

$34.48

Intervallo di 1 settimana:

$33.01

$35.58

Portata 52W:

$22.90

$36.45

Alkermes Plc Stock (ALKS) Company Profile

Nome

Alkermes Plc

Settore

Healthcare (1176)

Industria

Drug Manufacturers - Specialty & Generic (1)

Telefono

00-353-1-772-8000

Indirizzo

CONNAUGHT HOUSE, DUBLIN 4

Dipendente

1,800

Cinguettio

@alkermes

Prossima data di guadagno

2024-10-24

Ultimi documenti SEC

ALKS's Discussions on Twitter

Confronta ALKS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALKS Alkermes Plc	34.03	5.53B	1.51B	333.35M	315.22M	1.95
ZTS Zoetis Inc	161.26	72.21B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.01	47.43B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.15	45.90B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.33	18.71B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	131.26	13.96B	612.78M	-86.37M	-62.91M	-0.87

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-03-04	Aggiornamento	UBS	Sell → Neutral
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-11-05	Aggiornamento	Stifel	Hold → Buy
2024-06-17	Iniziato	TD Cowen	Buy
2024-03-19	Iniziato	Robert W. Baird	Outperform
2024-02-20	Downgrade	UBS	Neutral → Sell
2023-11-20	Ripresa	JP Morgan	Neutral
2023-10-24	Aggiornamento	Evercore ISI	In-line → Outperform
2023-10-17	Iniziato	UBS	Neutral
2022-11-03	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-14	Aggiornamento	BofA Securities	Underperform → Neutral
2022-08-16	Iniziato	Piper Sandler	Neutral
2022-04-22	Ripresa	Goldman	Buy
2022-04-20	Iniziato	Goldman	Buy
2022-01-27	Aggiornamento	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Iniziato	Citigroup	Neutral
2021-10-07	Aggiornamento	Jefferies	Hold → Buy
2021-09-02	Downgrade	BofA Securities	Neutral → Underperform
2020-10-15	Aggiornamento	Mizuho	Neutral → Buy
2020-07-30	Downgrade	Goldman	Neutral → Sell
2020-02-14	Downgrade	BofA/Merrill	Buy → Neutral
2020-02-14	Reiterato	H.C. Wainwright	Neutral
2020-02-14	Downgrade	JP Morgan	Overweight → Neutral
2020-02-06	Iniziato	Mizuho	Neutral
2020-01-31	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2019-09-05	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Aggiornamento	Goldman	Sell → Neutral
2019-05-31	Iniziato	H.C. Wainwright	Neutral
2019-05-01	Downgrade	Citigroup	Buy → Neutral
2018-12-19	Downgrade	Goldman	Neutral → Sell
2018-12-14	Iniziato	Wolfe Research	Underperform
2018-12-13	Downgrade	Credit Suisse	Outperform → Underperform
2018-11-05	Iniziato	Piper Jaffray	Neutral
2018-08-07	Iniziato	Stifel	Hold
2018-06-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Iniziato	B. Riley FBR, Inc.	Buy
2018-05-16	Aggiornamento	Citigroup	Neutral → Buy
2018-05-11	Iniziato	BofA/Merrill	Buy

Mostra tutto

Alkermes Plc Borsa (ALKS) Ultime notizie

11:30 AM

Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? - Yahoo Finance

11:30 AM

10:57 AM

Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

10:57 AM

09:08 AM

Alkermes PLC Reports Q4 Revenue of $430 Million, Beating Estimat - GuruFocus.com

09:08 AM

09:00 AM

Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years - Yahoo Finance

09:00 AM

06:33 AM

Alkermes (NASDAQ:ALKS) shareholders have earned a 19% CAGR over the last five years - Simply Wall St

06:33 AM

Mar 13, 2025

Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says - Marketscreener.com

Mar 13, 2025

RBC Capital Initiates Coverage of Alkermes (ALKS) with Sector Perform Recommendation - Nasdaq

Mar 13, 2025

S&P 500 Futures Drop in Premarket Trading; Alkermes, Intel Lead - Barron's

Mar 13, 2025

Alkermes initiated with a Sector Perform at RBC Capital - TipRanks

Mar 13, 2025

Charles Schwab Investment Management Inc. Sells 38,088 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 13, 2025

Mar 12, 2025

Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights - Investing.com India

Mar 12, 2025

Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com South Africa

Mar 12, 2025

Alkermes to Participate in Upcoming Investor Conferences - GuruFocus.com

Mar 12, 2025

Mar 09, 2025

Alkermes Plc to Host Earnings Call - ACCESS Newswire

Mar 09, 2025

Alkermes plc (NASDAQ:ALKS) Shares Bought by Smartleaf Asset Management LLC - Defense World

Mar 09, 2025

Proficio Capital Partners LLC Buys New Stake in Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 09, 2025

Mar 08, 2025

Y Intercept Hong Kong Ltd Invests $413,000 in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Mar 06, 2025

Mar 05, 2025

UBS Upgrades Alkermes (ALKS) - Nasdaq

Mar 05, 2025

Bank of New York Mellon Corp Has $61.45 Million Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 05, 2025

Alkermes (NASDAQ:ALKS) Upgraded to Neutral at UBS Group - Defense World

Mar 05, 2025

Mar 04, 2025

UBS Upgrades Alkermes to Neutral From Sell, $38 Price Target -March 04, 2025 at 08:27 am EST - Marketscreener.com

Mar 04, 2025

Alkermes upgraded to Neutral from Sell at UBS - TipRanks

Mar 04, 2025

Mar 01, 2025